Drugs / GSK3368715
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03666988 | Oct 2018 → Mar 2021 | neoplasm | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3368715 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03666988 ↗ |
| Action | Inhibit | “GSK3368715, a type I PRMT inhibitor, in patients with advanced ” PMID 37237172 ↗ May 2023 |
| Route | Oral | “administered orally once daily” NCT03666988 ↗ |